Biocytogen provides hundreds of genetically modified off-the-shelf BIOMICE for basic and preclinical research. Our large collection of humanized immune-checkpoint, humanized cytokine/cytokine receptor, humanized TAA mice, and immunodeficient mice, which have been published in hundreds of studies, facilitate in vivo efficacy assessments of novel anti-human immunotherapies.
RenMab™ mice contain the entire human immunoglobulin variable domain, which streamlines discovery and eliminates the need for humanization. Our RenLite® model contains a fixed common light chain that eliminates chain mispairing during bispecific antibody development. Immunized RenMice undergo in vivo selection and affinity maturation to generate quality antibody hits.
Our advanced genome editing technologies have been leveraged by our own development scientists to create hundreds of animal and cell models used in biomedical research ...
Biocytogen’s antibody BD and licensing team is pleased to attend and host 1-on-1 meetings at the 17th annual BIO-Europe Spring, taking place March 20–22, 2023 ...
We’re attending AACR 2023, held from April 14-19 in Orlando, Florida! For the latest advances, service offerings, and promotions, register now to visit our team ...
Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen offers solutions for preclinical antibody drug discovery and efficacy validation. Our CRO & vivarium sites in Boston and China have enabled global partnerships with numerous academic and industrial clients to accelerate basic and preclinical research.
Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen offers solutions for preclinical antibody drug discovery and efficacy validation. Our CRO & vivarium sites in Boston and China have enabled global partnerships with numerous academic and industrial clients to accelerate basic and preclinical research.
Founded in 2009, our proprietary, efficient genetic engineering technologies have made us a global leader in animal and cell model generation. Development of our advanced chromosome engineering technology and high-throughput antibody discovery platform further expanded our capabilities for therapeutic antibody discovery using our fully human antibody mice.
With the largest catalog of humanized models available and an experienced in vivo pharmacology team, we have completed over 1,300 drug evaluation projects. Our fast turnaround times and dedication to superior customer service have set us apart.
Whether you need gene editing, antibody discovery, or pharmacology services, our cutting-edge platforms provide fast and reliable solutions.